Notably, our finding that under expression of LURAP1 is associated with better response to atezolizumab is consistent with previous evidence from TCGA bladder cancer data, where hypermethylation of five CpG sites in LURAP1 (resulting in reduced expression) was linked to improved overall survival (30). The gene discussed is LURAP1; the disease is urinary bladder carcinoma.